AUROBINDO PHARMA USA, INC.
AUROBINDO PHARMA USA, INC. reported $120.1K in payments to physicians and teaching hospitals across 35 transactions in CMS Open Payments PY 2024.
Pharmaceutical payment transparency data for AUROBINDO PHARMA USA, INC.. Ranked #1065 of 1,797 companies by total payments. Source: CMS Open Payments, Program Year 2024.
Payment Overview
Total Payments
$120.1K
0.0% of all payments
Transactions
35
$3.4K avg
Recipients
35
$3.4K avg
Industry Rank
#1065
of 1,797 companies
What the Data Shows for AUROBINDO PHARMA USA, INC.
In Program Year 2024, AUROBINDO PHARMA USA, INC. reported $120,074.96 in payments to 35 physicians and teaching hospitals across 35 individual transactions — an average of $3.4K per transaction and $3.4K per recipient. That total places AUROBINDO PHARMA USA, INC. at rank #1065 out of 1,797 companies in the CMS Open Payments database, representing 0.0% of all industry payments reported nationwide for the year. Payment volume at this scale is characteristic of manufacturers with broad prescriber engagement, active clinical research programs, or patented therapies generating ongoing royalty obligations.
The payment mix for AUROBINDO PHARMA USA, INC. spans 3 distinct categories defined by CMS — including general payments (consulting, speaker fees, meals, travel), research payments tied to clinical trials, and ownership or investment interests. The largest single category is "Consulting Fee" at $117.7K, accounting for 98.1% of the company's reported total and 8 transactions. This distribution matters because different payment types carry different regulatory and ethical implications: research funding supports clinical development, while general payments like meals and speaker fees have been studied for their correlation with prescribing patterns in peer-reviewed journals such as JAMA Internal Medicine.
Recipient concentration is another useful lens. The top 5 recipients of payments from AUROBINDO PHARMA USA, INC. received $0.00 combined — 0.0% of the company's total — with the remaining 100.0% distributed across the rest of the 35 recipients. A relatively distributed top-5 share suggests broader engagement across the prescriber community rather than concentration among a handful of high-value relationships. All figures above are drawn directly from the CMS Open Payments Public Use Files for PY2024 and are disclosed under the Physician Payments Sunshine Act; this page summarizes reported financial transfers and does not represent medical advice or judgment about individual prescribing decisions.
Payment Breakdown by Type
AUROBINDO PHARMA USA, INC. made 3 types of payments. "Consulting Fee" accounts for 98.1%.
98.1% · 8 transactions
1.4% · 15 transactions
0.5% · 12 transactions
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $117.7K | 8 | 98.1% |
| Travel and Lodging | $1.7K | 15 | 1.4% |
| Food and Beverage | $657.43 | 12 | 0.5% |
Payment Size Analysis
Average transaction size: $3.4K. Average per recipient: $3.4K.
Total Amount
$120,074.96
Avg per Transaction
$3.4K
Avg per Recipient
$3.4K
Payment Transparency Context
The Physician Payments Sunshine Act (part of the Affordable Care Act) requires pharmaceutical and medical device manufacturers to report payments and transfers of value to physicians and teaching hospitals. These payments can include consulting fees, research grants, speaker fees, food and beverages, travel, royalties, and other forms of compensation.
Industry Total (2024)
$13.3B
across 1,797 companies
AUROBINDO PHARMA USA, INC. Share
0.0%
#1065 by total payments
Related Healthcare Data
Explore related drug and healthcare provider data from other federal sources
PlainMeds — Drug Information
FDA drug data for 682 medications including interactions and alternatives. Look up drugs that AUROBINDO PHARMA USA, INC. may manufacture.
PlainDoctor — Provider Data
CMS provider data for 7M+ healthcare providers. Search for physicians who may be recipients of pharmaceutical payments.
PlainHospital — Hospital Quality
CMS Hospital Compare data for 5,400+ hospitals. View quality ratings for teaching hospitals that receive pharmaceutical payments.
PlainRecalls — FDA Recalls
FDA drug and device recall data. Check recall history for products manufactured by AUROBINDO PHARMA USA, INC..
PlainProcedure — Procedure Costs
Medicare procedure cost data for 9,200+ procedures. See what hospitals charge for medical procedures and how costs vary by state.
Learn More About Pharma Payments
In-depth guides on pharmaceutical industry payment transparency
Understanding Open Payments
How the Sunshine Act works and what payment data means for patients and physicians.
Drug Company Marketing Practices
How pharmaceutical companies market to healthcare professionals and why it matters.
Pharma Payment Types Explained
A guide to the different types of payments pharmaceutical companies make to physicians.
Companies with Similar Payment Volumes
Pharmaceutical companies with payment totals similar to AUROBINDO PHARMA USA, INC.
Frequently Asked Questions
How much did AUROBINDO PHARMA USA, INC. pay to physicians and hospitals in 2024? ▾
How many physicians received payments from AUROBINDO PHARMA USA, INC.? ▾
What types of payments did AUROBINDO PHARMA USA, INC. make? ▾
How does AUROBINDO PHARMA USA, INC. rank among pharmaceutical companies? ▾
What is the average payment size from AUROBINDO PHARMA USA, INC.? ▾
Are the top recipients concentrated for AUROBINDO PHARMA USA, INC.? ▾
Where does the payment data for AUROBINDO PHARMA USA, INC. come from? ▾
Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.3B across 1,797 companies.
Related
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology — how this data is sourced, computed, and verified.
